US › Healthcare

XTL Biopharmaceuticals Ltd ADR (XTLB)

US · Healthcare · Biotechnology

$2.40+0.42%

Last close · 2026-09-17

Latest quarter · ended 2025-03-31

Revenue

$289,000

Net profit

$-255,000

Profit YoY

-152.6%

EPS

$-0.01

EPS estimate

$0.00

Net margin

-88.2%

Key statistics

Market cap

$6.3M

Forward P/E

0.0

P/B

1.90

Book value

$0.00

EPS (TTM)

$-0.36

52-week high

$10.28

52-week low

$2.01

50-day MA

$2.78

200-day MA

$2.90

Beta

0.45

Analyst view

with an average price target of $30.00.

Shareholding

Insiders

21.44%

Institutions

0.21%

Largest institutional holders

Fund	Stake
Rhumbline Advisers	0.24%
GAMMA Investing LLC	0.05%
Tower Research Capital LLC	0.01%
Morgan Stanley - Brokerage Accounts	0.00%
Noked Israel Ltd	0.00%
XTX Topco Ltd	0.00%
SmartHarvest Portfolios, LLC	0.00%
Citadel Advisors Llc	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for XTL Biopharmaceuticals Ltd ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.